Matricelf’s Spinal Cord Implants

About

Matricelf's spinal cord implants are part of a groundbreaking regenerative medicine platform aimed at treating spinal cord injuries (SCI). The technology involves 3D printing and engineering autologous neural implants, derived from the patient's own cells and extracellular matrix. This approach ensures compatibility and reduces the risk of immune rejection. The process begins with a biopsy of omentum tissue, which is then processed into a thermo-responsive hydrogel. Patient cells are reprogrammed into induced pluripotent stem cells (iPSCs), which are differentiated into functional neural tissue within the hydrogel. These implants have shown promising results in preclinical trials, with an 80% success rate in restoring walking ability in mice with chronic paralysis. Matricelf is preparing for human clinical trials, aiming to offer a transformative treatment for SCI patients. The technology holds potential for treating various medical conditions beyond spinal cord injuries. By using autologous tissue, Matricelf's approach provides a highly personalized and innovative solution for regenerative medicine, offering hope for improved motor, sensory, and autonomic functions in paralyzed patients.